Survodutide: Dual GLP-1 / Glucagon Agonist Research Profile

Overview

Survodutide (BI 456906) is an investigational once-weekly peptide being developed by Boehringer Ingelheim and Zealand Pharma. It is a dual agonist of the GLP-1 and glucagon receptors — the same receptor combination that distinguishes it from tirzepatide (which is GLP-1 + GIP).

Mechanism of Action

• GLP-1 receptor: drives appetite reduction, delayed gastric emptying, and glucose-dependent insulin release.
• Glucagon receptor: adds an energy-expenditure component; historically a counter-regulatory hormone, in the context of simultaneous GLP-1 engagement the glucagon arm preferentially drives fat oxidation and hepatic lipid handling without causing hyperglycemia.

This ratio-engineered design is what makes survodutide prominent in MASH / hepatic-outcome research, not just obesity.

Research Evidence

• Obesity Phase 2: reported weight reductions in the high-teens percent range at 46 weeks at the highest dose.
• MASH Phase 2: drew particular attention because glucagon engagement is mechanistically plausible for hepatic fat and fibrosis signals that GLP-1 monotherapy targets indirectly.
• Phase 3: pivotal readouts in obesity and MASH are the next milestone.

Why It Matters

Survodutide is the clearest current example of why glucagon receptor engagement is back in the metabolic conversation. It bridges obesity pipelines and MASH pipelines with a single mechanism.

Safety Framing

Typical incretin-class safety themes apply (GI tolerability, pancreatitis signals, gallbladder events, heart-rate modulation). Glucagon physiology also means careful dose-titration design is central to development.

Storage

• Temperature: 2–8°C
• Do not freeze
• Protect from light

This information is for research and educational purposes only. Survodutide is investigational and not approved for human use.